No-Rinse Solution (NS) for Joint Infections

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lenox Hill Hospital, New York, NY
Joint Infections+3 More
No-Rinse Solution (NS) - Other
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigation). The Next Science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than SOC (saline) arm

Eligible Conditions

  • Joint Infections

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: at 90 days

at 90 days
infection rate
Hour 24
QT prolongation

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Standard of Care
1 of 2
The Next Science treatment
1 of 2
Active Control
Experimental Treatment

936 Total Participants · 2 Treatment Groups

Primary Treatment: No-Rinse Solution (NS) · No Placebo Group · N/A

The Next Science treatment
Other
Experimental Group · 1 Intervention: No-Rinse Solution (NS) · Intervention Types: Other
Standard of Care
Other
ActiveComparator Group · 1 Intervention: Saline irrigation · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 90 days
Closest Location: Lenox Hill Hospital · New York, NY
Photo of New York 1Photo of New York 2Photo of New York 3
2003First Recorded Clinical Trial
1 TrialsResearching Joint Infections
88 CompletedClinical Trials

Who is running the clinical trial?

Northwell HealthLead Sponsor
409 Previous Clinical Trials
289,274 Total Patients Enrolled
Next ScienceUNKNOWN
1 Previous Clinical Trials
700 Total Patients Enrolled
Giles ScuderiPrincipal InvestigatorNorthwell Health
1 Previous Clinical Trials
700 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have poorly treated hypertension.
You have a history of bronchospastic disease.
You have poorly treated diabetes.
You have a disease with intermittent exacerbations.
You are an anesthesiologist.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.